NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA

Core Points - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities between July 30, 2024, and January 8, 2025, of the April 14, 2025, lead plaintiff deadline [1] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3][6] Company Details - The lawsuit claims that during the Class Period, Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, which is aimed at treating alpha-1 antitrypsin deficiency-associated lung disease [5] - Defendants allegedly failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference due to cost-effectiveness and efficiency, making NTLA-3001 an inefficient program for Intellia [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]